Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

ADE regimen

View Patient Information
A regimen consisting of high-dose cytarabine (Ara-C), daunorubicin and etoposide, that is used for the treatment of pediatric and adult acute myeloid leukemia (AML).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADE
AraC-daunorubicin-etoposide regimen
cytarabine-daunorubicin-etoposide regimen
cytarabine/daunorubicin/etoposide
high-dose cytarabine-daunorubicin-etoposide regimen
high-dose cytarabine/daunorubicin/etoposide
high-dose cytarabine/daunorubicin/etoposide regimen
MRC AML10 study-ADE regimen
Abbreviation:ARA-C/DNR/VP-16
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search